Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 1,001–1,100 of 1,676
Hipertrigliceridemia grave. Características clínicas y manejo terapéutico
Masson, W. M., Rossi, E., Siniawski, D. A., Damonte, J. I., Halsband, A., Barolo, R., & Scaramal, M. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.03.005 · Cited by 16
The Rise and Fall “ing” of the HDL Hypothesis
Feghaly, J., & Mooradian, A. D. (2020) · Drugs · doi:10.1007/s40265-020-01265-4 · Cited by 9
Wang, K., Liang, C., Yeh, L., Liu, K., Chen, C., Chen, J., Chen, H., & Wang, H. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12635 · Cited by 9
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 11
Nam, G. E., Huh, Y., Jung, J., Han, K., Kim, S. M., & on Behalf of the Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1259 · Cited by 10
Manichaikul, A. W., Lin, H., Kang, C., Yang, C., Rich, S. S., Taylor, K. D., Guo, X., Rotter, J. I., Johnson, W. C., Cornell, E. S., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03304-0 · Cited by 7
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_21 · Cited by 14
Development and validation of novel automatable assay for cholesterol efflux capacity
Mutsuda, Y., Miyakoshi, T., Horiuchi, Y., Kameda, T., Tozuka, M., & Ohkawa, R. (2023) · Bioscience Reports · doi:10.1042/bsr20221519 · Cited by 8
Antilipidemic Drug Therapy Today and in the Future
Kramer, W. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_15 · Cited by 8
Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy
Basani, S., & Garg, A. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.08.004 · Cited by 8
HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack
Hassan, M. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.37 · Cited by 10
“02), with apparent clinical benefit if baseline LDL-C level was above 58mg/dL.(12) Indeed, it might not be expected to get clinical benefit if patients were on the flat part of the event curve.”
BackgroundDyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease
Gonzalez, L., Helkin, A. W., & Gahtan, V. (2016) · Vascular and Endovascular Surgery · doi:10.1177/1538574416628655 · Cited by 8
“Most recently, a similar study ending in 2014, HPS-2-THRIVE (Heart Protection Study 2Treatment of HDL to Reduce the Incidence of Vascular Events), included patients from 6 countries comparing statin monotherapy to the addition of niacin.(76) This study included an analysis of patients with claudication and cerebrovasc…”
ResultHigh-density lipoprotein: quantity or quality?
Τζιόμαλος, Κ. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.67 · Cited by 7
“Indeed, treatment with niacin had no effect on cardiovascular morbidity in patients with established CVD in the atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIMHIGH) and in the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of…”
BackgroundMessas, N., Dubé, M., & Tardif, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0679-5 · Cited by 8
Lamprecht, D. G., Shaw, P. B., King, J. B., Hogan, K. N., & Olson, K. L. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.007 · Cited by 10
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Heier, M., Ofstad, A. P., Borja, M. S., Brunborg, C., Endresen, K., Gullestad, L. L., Birkeland, K. I., Johansen, O. E., & Oda, M. N. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.005 · Cited by 8
Circulating selenium and prostate cancer risk: a Mendelian randomization analysisPreprint
Yarmolinsky, J., Bonilla, C., Haycock, P., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/223248 · Cited by 8
Haghikia, A., & Landmesser, U. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.03.003 · Cited by 8
Risk Factors in Cardiovascular Disease
Rosamond, W. D., & Quah, S. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00294-5 · Cited by 9
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
The role of high-density lipoproteins in sepsis
Brunham, L. R. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100728 · Cited by 11
Zhang, C., Xie, Y., Zhou, J., Zhang, C., Xiang, Q., Zhong, Y., Xiao, J., Feng, J., Liao, B., Chen, X., et al. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70372 · Cited by 9
“Clinical studies have indicated that niacin and fibrates do not show significant advantages in reducing cardiovascular event rates in patients with CHD and often cause discomfort such as gastrointestinal issues, liver dysfunction, and hyperuricemia (Group THTC 2014; Regemorter et al. 2022).”
Zhu, B., Yu, X., Lu, H., Su, M., Li, X., Jin, J., Yan, Y., & Jin, Y. C. (2025) · Bone · doi:10.1016/j.bone.2025.117651 · Cited by 8
Yeh, J., Syue, S.-H., Lin, C., Hsu, C. Y., Shae, Z., & Kao, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00889 · Cited by 7
Cochran, B. J., Manandhar, B., & Rye, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_9 · Cited by 9
The need for new clinical trials of old cardiovascular drugs
Granger, C. B., Pocock, S., & Gersh, B. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00819-1 · Cited by 7
Laron, Z., & Werner, H. (2023) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2023.101548 · Cited by 9
Toth, P. P., Ferrières, J., Waters, M., Mortensen, M. B., Lan, N. S. R., & Wong, N. D. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1220017 · Cited by 9
The pathophysiology of excess plasma-free cholesterol
Gillard, B. K., Rosales, C., Gotto, A. M., & Pownall, H. J. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000899 · Cited by 7
Measuring lipoprotein(a) for cardiovascular disease prevention – in whom and when?
Thomas, P. E., Vedel‐Krogh, S., & Nordestgaard, B. G. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001104 · Cited by 8
Yang, R., Wu, S., Zhao, Z., Deng, X., Deng, Q.-Y., Wang, D., & Liu, Q. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02420-7 · Cited by 9
“Although HDL does not appear to play a direct role in CAD [41–43], the functional characteristics of the HDL particle, particularly apoA1, may have an influence [44].”
Miller, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001136 · Cited by 7
Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes
Guardiola, M., Rehues, P., Amigó, N., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Girona, J., Martínez‐Montoro, J. I., Ortega, E., Pérez, A., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14214 · Cited by 8
“10,11 Paradoxically, therapeutic interventions aimed at lowering TG levels 12,13 or increasing HDLc levels 14 have not consistently shown a decrease in cardiovascular events, 15 while therapy directed at lowering LDLc levels (even within the normal range) does, independently of the therapy used.”
Reilly, N. A., Dekkers, K. F., Molenaar, J., Arumugam, S., Kuipers, T. B., Ariyürek, Y., Hoeksema, M. A., Jukema, J. W., & Heijmans, B. T. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.09.002 · Cited by 8
Quispe, R., Al-Hijji, M. A., Swiger, K. J., Martin, S. S., Elshazly, M. B., Blaha, M. J., Joshi, P. H., Blumenthal, R. S., Sniderman, A. D., Toth, P. P., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.05.005 · Cited by 7
HDL function as a predictor of coronary heart disease events: time to re-assess the HDL hypothesis?
Rye, K., & Ong, K. L. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00205-3 · Cited by 8
Back to the future: the urgent need to re-introduce streamlined trials
Collins, R. (2018) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy001 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Schwartz, L. M., Woloshin, S., Lu, Z., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006073 · Cited by 7
Targeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 9
“[51], more recent trials have failed to demonstrate this effect in the statin-treated patient [8,52].”
ResultMcEvoy, J. W., Whelton, S. P., & Blumenthal, R. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00038-x · Cited by 10
HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS
Cordero, A., Muñoz‐García, N., Padró, T., Vilahur, G., Bertomeu‐González, V., Escribano, D., Flores, E., Zuazola, P., & Badimón, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065391 · Cited by 7
Progress and Prospects of MXene-Based Hybrid Composites for Next-Generation Energy Technology
Chetana, S., Abdah, M. A. A. M., Thakur, V. N., et al. (2023) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/ad0c64 · Cited by 7
Efficacy and safety of ezetimibe plus atorvastatin therapy
Foody, J. M., Toth, P. P., Tershakovec, A. M., Musliner, T., Tomassini, J. E., Lowe, R. S., Neff, D., & Davis, H. R. (2014) · Clinical Lipidology · doi:10.2217/clp.14.36 · Cited by 11
Reconstituted High-Density Lipoprotein Therapies: A Cause for Optimism
Javaheri, A., Kolansky, D. M., & Cuchel, M. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304156 · Cited by 8
The past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Cardiovascular risk reduction: the future of cholesterol lowering drugs
Malham, S. B., & Goldberg, A. C. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.007 · Cited by 10
“Niacin therapy was associated with an increased incidence of serious adverse events (GI, musculoskeletal, skin, infection, and bleeding) and higher risk of new cases of type 2 diabetes [33].”
BackgroundStein, J. H. (2016) · Europe PMC (PubMed Central) · Cited by 9
Seely, E. W., & Grinspoon, S. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00002-8 · Cited by 11
β 3 -Adrenergic receptor regulates hepatic apolipoprotein A-I gene expression
Cao, X., & Li, Y. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.007 · Cited by 7
Acute pancreatitis secondary to oral contraceptive-induced hypertriglyceridemia: a case report
Stumpf, M. A. M., Kluthcovsky, A. C. G. C., Okamoto, J. M., Schrut, G. C. A., Cajoeiro, P. D. O., Chacra, A. P. M., & Bizeli, R. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1473365 · Cited by 7
Qi, Y., Li, Y., Wang, Z., Wang, X., Meng, H., Li, W., Chen, D.-C., Li, M., Liu, J., & An, S. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00626-7 · Cited by 7
“1 Years Landray [33] 2014 UK,Scandinavia,China 6575 64.”
InfluentialEfficacy and Safety of Naproxen for Acute Pain
Weisman, S. R. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0064 · Cited by 10
Zheng, B., Goto, S., Clementi, R. A., Feaster, J., Duffy, D., Dalitz, P., Airey, J., Korjian, S., Tortorici, M. A., Roberts, J., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13361 · Cited by 7
Hyperlipidemia and cardiovascular disease: reinforcement for ‘lower is better’
Burkhardt, R. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000221 · Cited by 8
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Collins, P. D., & Sattar, N. A. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0795-9 · Cited by 7
Subramanian, S., & Chait, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65798-7 · Cited by 9
NAD+ enhancers as therapeutic agents in the cardiorenal axis
Marin-Blazquez, M., Rovira, J., Ramírez-Bajo, M. J., Perez, R. Z., & Rabadán-Ros, R. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01903-4 · Cited by 7
Akinlonu, A. A., Boffa, M. B., Lyu, C., Zhong, J., Jindal, M., Fadzan, M., Garshick, M. S., Schwartzbard, A. Z., WEINTRAUB, H. S., Bredefeld, C., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.008 · Cited by 9
Cardiovascular disease lipids and lipoproteins biomarker standardization
Lyle, A. N., Danilenko, U., Sugahara, O., & Vesper, H. W. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2462817 · Cited by 8
“Indeed, niacin supplements and cholesteryl-ester transfer protein inhibitors, tested in the HPS2-THRIVE and REVEAL trials, respectively, increased HDL-C [59,60]; however, CVD outcomes trials ended due to non-ideal pharmacokinetics, futility, and serious adverse events.”
Li, S., Fu, Z., & Zhang, W. (2025) · BMC Public Health · doi:10.1186/s12889-025-22251-z · Cited by 8
“However, subsequent randomized controlled trials have been terminated due to futility in demonstrating the cardio-vascular benefit of high-dose niacin or cholesteryl ester transfer protein (CETP) inhibitors, despite significant increases in HDL cholesterol concentrations [4–6].”
Montastier, É., Ye, R. Z., Noll, C., Amrani, M., Frisch, F., Fortin, M., Bouffard, L., Phoenix, S., Sarrhini, O., Cunnane, S. C., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177563 · Cited by 6
Roger, G., Packard, C. J., Masana, L., Laufs, U., Catapano, A. L., & Steg, P. G. (2025) · Heart · doi:10.1136/heartjnl-2025-325765 · Cited by 6
Ashraf, T., Devi, N., Aradhna, F., Devi, S., Nancy, F., Kumar, A., Ameer, F., Absar, F., Kumar, L., Kumar, S., et al. (2025) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000003505 · Cited by 6
“The HPS2-THRIVE trial, involving over 25 000 patients, and the AIM-HIGH trial, with over 3400 participants, both showed no reduction in major vascular events [ 41 , 42 ] .”
HDL-C: Helpful, harmful, hopeful, or guilty by association
McLean, P., Mathew, D., Chandrasekhar, S. A., Guynn, N., Razavi, A. C., Quyyumi, A. A., Mehta, A., & Sperling, L. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.017 · Cited by 7
Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies
Nasrallah, N., Atallah, Harb, T., Gerstenblith, G., & Leucker, T. M. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70127 · Cited by 8
Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies
Al‐Horani, R. A., Selico-Dunn, A. C., & Smith, E. L. S. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07810-1 · Cited by 11
“Furthermore, large-scale trials, including AIM-HIGH [15] and HPS2-THRIVE [16], failed to demonstrate cardiovascular benefit, even though AIM-HIGH participants experienced a 25% reduction in Lp(a).”
Lipoprotein(a) – treatments in development
Tomlinson, B., & Law, C. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601062 · Cited by 6
“Likewise, ERN combined with laropiprant had no significant CV benefit when added to statin therapy in patients with ASCVD in the HPS2-THRIVE (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events) study (NCT00461630) [27].”
Yu, B., Zhao, S., Hu, D., Ambegaonakr, B. M., DYSIS-China Study Investigators, DYSIS-China Study Investigators, Er, B. A. J., Guiwen, C., Buxing, C., Hong, C., et al. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv018 · Cited by 6
Lagerstedt, J. O., Dalla‐Riva, J., Marinković, G., Giudice, R. D., Engelbertsen, D., Burlin, J., Petrlová, J., Lindahl, M., Bernfur, K., Melander, O., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12817 · Cited by 7
Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review
Sinha, M., Maged, R., Tarar, P., Bandi, V. V., Koneru, H. M., & Sarwar, H. (2024) · Cureus · doi:10.7759/cureus.69824 · Cited by 10
“…lipoprotein receptor (LDLR) [20,23,26-30, Inhibitors -25% Increased removal by LDLR [32-34] Niacin -20% Decreased production of apo(a) [17,35,36,45] CoQ10 0-15% Suppression of oxidative stress and increased production of HDL [24,25] Lp(a) Apheresis 60% (per procedure); 30% (long term)…”
BackgroundInfluentialZhu, D., Judge, P. K., Staplin, N., Haynes, R., & Herrington, W. G. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae210 · Cited by 7
“Smaller and shorter trials also inadequately assess safety, because these drugs will typically be taken by an individual for many years [32 , 33 ].”
Jain, R. K., & Laiteerapong, N. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0665-7 · Cited by 6
Ongoing challenges for pharmacotherapy for dyslipidemia
Pisaniello, A. D., Scherer, D. J., Kataoka, Y., & Nicholls, S. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.986094 · Cited by 6
“While there is considerable interest in Lp(a) as an important factor driving atherosclerosis [19], agents that lower Lp(a) have not been demonstrated to reduce clinical events (niacin, oestrogen) [27,28,101].”
BackgroundMonoclonal Antibodies for Lipid Management
Feinstein, M. J., & Lloyd‐Jones, D. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0593-2 · Cited by 6
Whelton, S. P., Dardari, Z., Marshall, C. H., Ahmed, H. M., Brawner, C. A., Ehrman, J. K., Keteyian, S. J., Al-Mallah, M. H., & Blaha, M. J. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.02.009 · Cited by 6
Brar, A., Santana, J. M., Salifu, M. O., & Brown, C. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82831 · Cited by 7
“The relative risk of myopathy with niacin-laropiprant versus placebo was also higher in Chinese patients [132].”
BackgroundLipoprotein(a) Testing and Emerging Therapies
Mayo-Malasky, P., & Frishman, W. H. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000295 · Cited by 6
Managing the Burden of Dementia-Related Delusions and Hallucinations
Small (2020) · The Journal of Family Practice · doi:10.12788/jfp.0065 · Cited by 6
Carland, C., Hansra, B., Parsons, C., Lyubarova, R., & Khandelwal, A. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100155 · Cited by 10
“For example, clinical trials on niacin included only a very small proportion of women, even in more recent trials like HPS2-THRIVE (17 % women) in 2014 and AIM-HIGH ( 15 % women) in 2011 [39,40].”
MethodNon-innocuous Consequences of Metabolic Oxidation of Alkyls on Arenes
Claesson, A., & Parkes, K. E. B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00833 · Cited by 6
Lipid lowering therapy in 2022 and beyond - How far we have come
Saseen, J. J., & Virani, S. S. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.008 · Cited by 6
Association of Dietary Niacin Intake with Diabetes in Adults in the United States
Liu, C., Duan, W., & Xu, W. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2038-0476 · Cited by 8
Liu, H., Wang, F., Xia, H., Pan, D., Yang, L., Wang, S., Zhao, F., & Sun, G. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.03.042 · Cited by 9
Gupta, A., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113758 · Cited by 7
“The addition of 2 g of extended-release niacin and 40 mg of laropiprant in the HPS2-THRIVE study did not result in a lowering of the incidence of major cardiovascular events compared to placebo [27].”
BackgroundIs Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes
Ma, G. S., Chiou, T. T., & Wilkinson, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01937-z · Cited by 5
“Niacin has been shown to reduce Lp(a) levels by up to 30%, though concerns over tolerability as well as the unknown cardiovascular benefit have limited recommendations for its use [49, 50].”
BackgroundYuen, T., Mancini, G. B. J., Hegele, R. A., & Pearson, G. J. (2023) · CJC Open · doi:10.1016/j.cjco.2023.11.015 · Cited by 7
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 11
“There was an unexpected increase in infection rate by 1.4% with the use of niacin [57].”
BackgroundInfluentialNiacin fails to reduce vascular events in large randomised trial
McCarthy, M. R. (2014) · BMJ · doi:10.1136/bmj.g4774 · Cited by 6
Niacin for Reduction of Cardiovascular Risk
Landray, M., Haynes, R., & Armitage, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1411240 · Cited by 6
“Moreover, half the patients in HPS2-THRIVE had a normal HDL cholesterol level (mean, 1.14 mmol per liter).”
ResultInfluentialNicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs
Bloc’h, J. L., Leray, V., Nazih, H., Gauthier, O., Serisier, S., Magot, T., Krempf, M., Nguyen, P., & Ouguerram, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136934 · Cited by 10
Hu, M., Yang, Y., Ng, C., Lee, C. P., Lee, V. W. Y., Hanada, H., Masuda, D., Yamashita, S., & Tomlinson, B. (2015) · Medicine · doi:10.1097/md.0000000000000881 · Cited by 6
Lakshminarayan, D., Elajami, T. K., Devabhaktuni, S., & Welty, F. K. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.012 · Cited by 6
Advances in Lipid Therapy: The Role of Lipid Treatment in Women in Primary Prevention
Gulati, M., & Merz, C. N. B. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.008 · Cited by 6
Dunbar, R. L., Goel, H., Tuteja, S., Song, W., Nathanson, G., Babar, Z., Lalic, D., Gelfand, J. M., Rader, D. J., & Grove, G. L. (2017) · Journal of Lipid Research · doi:10.1194/jlr.d071696 · Cited by 9
Sisson, E. M., Pamulapati, L. G., Bucheit, J. D., Kelly, M. S., & Dixon, D. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2074 · Cited by 6
Masuda, Y., Kurikawa, N., & Nishizawa, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.041 · Cited by 6
Khetarpal, S. A., Babb, P. L., Zhao, W., Hancock-Cerutti, W. F., Brown, C. D., Rader, D. J., & Voight, B. F. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.002070 · Cited by 6
Regulation of apolipoprotein A-I gene expression by the histamine H1 receptor: Requirement for NF-κB
Haas, M. J., Jurado-Flores, M., Hammoud, R., Plazarte, G., Onstead‐Haas, L., Wong, N. C. W., & Mooradian, A. D. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.022 · Cited by 6
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.